🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

8 recruiting trials

for Immune Effector Cell Associated Neurotoxicity Syndrome

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma NCT07106671Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Siltuximab Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome NCT05643092n/a1 site📍 Shijiazhuang zhang shoulong Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma NCT06421675Phase 26 sites📍 Vancouver📍 Victoria📍 Hamilton Ontario Clinical Oncology Group (OCOG) · Tests: Elranatamab injection Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study NCT07169487Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Methylene Blue Temporal Characterization of Extracellular Vesicles During Cellular Therapy Using CAR-T Cells and During the Occurrence of Immune Effector Cell-Associated Neurotoxicity Syndrome NCT06706102Phase 41 site📍 Saint-Etienne Centre Hospitalier Universitaire de Saint Etienne · Tests: Biological tests, MRI, Neuropsychological tests Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma NCT05972135Phase 217 sites📍 Tucson📍 Denver📍 Denver SCRI Development Innovations, LLC · Tests: Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone Assessing DCog Short for Neurotoxicity in CAR-T NCT07403812NA1 site📍 Boston Beth Israel Deaconess Medical Center · Tests: DCog Short Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy NCT07390071NA1 site📍 Salt Lake City University of Utah · Tests: Home Automated Telemanagement (HAT) Patient Unit
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy